FiercePharmaOriginal article
{"a":[{"_":"Keenova gets on the good foot with Xiaflex trial win in rare tissue growth condition","$":{"href":"/pharma/keenova-gets-good-foot-successful-trial-xiaflex","hreflang":"en"}}]}
Phase 3positiveXiaflexPositive
AI Analysis
Summary
Keenova Therapeutics' Xiaflex demonstrated positive Phase 3 trial results for a third indication in a rare tissue growth condition, potentially supporting approval beyond its established use for Dupuytren's contracture and Peyronie's disease.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Phase 3 trial successful for third indication beyond Dupuytren's contracture and Peyronie's disease
Importance:7/10
Sentiment:
0.75
Phase 3clinical trialXiaflexDupuytren's contracturePeyronie's diseaserare diseaseapproval pathway
Read the original article
Published by FiercePharma on July 8, 2026 10:41 AM